IN TYPE 1 DIABETES

IT'S TIME TO GO BEYOND INSULIN ALONE

#ALLYFORINSULIN

A MOVEMENT IS STARTING

FIND OUT WHY

ADULT PATIENTS ARE NOT REACHING A1C GOAL OF <7%[1]

despite decades of advances in treatment and education, poor glycemic control persists for most patients with T1d.



CHALLENGES OF INSULIN ALONE

Insulin, the cornerstone of T1D therapy, is associated with several challenges including:

Hypoglycemia[2]

Weight gain which may lead to[3]:
- Obesity
- Hypertension
- Dyslipidemia

Complexity and demands of day-to-day management[2]

Given the challenges of managing T1D, insulin alone may not be enough.[2-5]

JOIN THE MOVEMENT

IT'S TIME TO GO BEYOND INSULIN ALONE

SANOFI Lexicon pharmaceuticals

1. Miller KM, Foster NC, Beck RW, et al. T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange Clinic Registry. Diabetes Care. 2015;38(6):971-978.

2. Aschner P, Horton E, Leiter LA, Munro N, Skyler JS; the Global Partnership for Effective Diabetes Management. Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. Int J Clin Pract. 2010;64(3):305-315.

3. Purnell JQ, Hokanson JE, Cleary PA, et al. The effect of excess weight gain with intensive diabetes treatment on cardiovascular disease risk factors and atherosclerosis in type 1 diabetes: Results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC) study. Circulation. 2013;127(2):180-187.

4. Martyn-Nemeth P, Quinn L, Penckofer S, Park C, Hofer V, Burke L. Fear of hypoglycemia: influence on glycemic variability and self-management behavior in young adults with type 1 diabetes. J Diabetes Complications. 2017;31(4):735-741.

5. Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3:153-165. doi:10.1016/j.cmet.2006.01.004.

©2018 Sanofi US and Lexicon Pharmaceuticals, Inc. All rights reserved. SAUS.SOTA.18.11.6475